Drug, bio-affecting and body treating compositions inventions 05/08

20080125347 - Amino acid substituted molecules: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also... Agent: Seed Intellectual Property Law Group PLLC

20080125350 - Branched polyalkylene glycols: The present invention provides a branched polyalkylene glycol wherein three or more single-chain polyalkylene glycols and a group having reactivity with an amino acid side chain, the N-terminal amino group or the C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity are bound; and... Agent: Fitzpatrick Cella Harper & Scinto

20080125346 - Infant formula: The present invention relates to a nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpxN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with... Agent: Foley And Lardner LLP Suite 500

20080125348 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125349 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125351 - Polymer-based sustained release device: This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080125352 - Unique integrin binding site in connective tissue growth factor: The invention relates to a connective tissue growth factor peptide that encompasses a CTGF binding site for an integrin such as αvβ3 or α5β1 and uses therefor. The invention also relates to agonists and inhibitors of the CTGF-integrin binding and methods of treating and preventing CTGF-related disorders.... Agent: Marshall, Gerstein & Borun LLP

20080125353 - Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080125354 - Selective inhibition of matrix metalloproteinases: Synthetic triple-helical peptides (THPs) are used for the design and synthesis of triple-helical transition state analog inhibitors. These inhibitors feature a phosphonate ester or phosphinic moiety in place of the scissle bond. These groups inhibit MMPs, and methods been developed for their convenient incorporation within a peptide sequence by solid-phase... Agent: Akerman Senterfitt

20080125359 - Antimicrobial peptides and methods of identifying the same: Antimicrobial peptides and methods of identifying the same are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20080125360 - Composition comprising pyy for the treatment of gastrointestinal disorders: The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of functional gastrointestinal disorders, such as irritable bowel disease and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080125357 - Compositions comprising a ligand of chemerinr: The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screening assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related... Agent: Edwards Angell Palmer & Dodge LLP

20080125355 - Endogenous peptide and active subfragments thereof: The present invention relates to a substantially pure biologically active consecutive anti-angiogenic polypeptide comprising the central region of human Histidine Rich Glycoprotein (HRGP). Said polypeptide is shown to comprise a potential endogenous, naturally occurring subfragment of human HRGP, comprising similar anti-angiogenic activities as the mature protein. The present invention also... Agent: Fish & Richardson P.C.

20080125366 - Insecticidal proteins derived from bacillus thuringiensis: The present invention relates to the field of plant pest control, particularly insect control. Provided are nucleotide sequences from Bacillus thuringiensis encoding insecticidal proteins. Further provided are methods and means for using said nucleotide sequence for controlling plant insect pests. It is emphasized that this abstract is provided to comply... Agent: Buchanan, Ingersoll & Rooney PC

20080125365 - Isolated complexes of covalently cross-linked endotoxin and modified md-2: Applicants have produced and isolated chemically cross-linked complexes of endotoxin and modified MD-2, and have developed methods of using these complexes.... Agent: Viksnins Harris & Padys Pllp

20080125362 - Method of screening compound preventing cells from infection with hepatitis c virus (hcv): The present invention relates to a screening method and identification method for a compound that inhibits the cell infection of hepatitis C virus (HCV), which comprises measuring affinity of a test compound for fibroblast growth factor receptor (FGFR) or the capability of blocking the binding thereof to HCV, and selecting... Agent: Fitzpatrick Cella Harper & Scinto

20080125368 - Methods: A method for aiding in the assessment of peritoneal membrane injury or complications of peritoneal dialysis in a patient, the method comprising the step of determining the level of CCL18 and/or angiogenin in a sample from the patient. The method may be for assessing the likely progression of peritoneal membrane... Agent: Nikolai & Mersereau, P.A.

20080125364 - Methods and compositions for treating epithelial cancers: Methods and compositions for modulating tight junction formation are provided.... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20080125358 - Methods for chk2 inhibitor patient selection: The present invention contemplates a method to identify subjects that either have a tumor, or are at risk for tumor development, that are responsive to various inhibitors of an activated-Chk2 protein. Such Chk2 inhibitors may comprise a benzimidazole core structure, and derivatives thereof. Other Chk2 inhibitors may comprise nucleic acids,... Agent: Peter G. Carroll Medlen & Carroll LLP

20080125363 - Polymer-linked pseudomonas exotoxin immunotoxin: The present invention relates to polymer conjugates of SS1P, and methods of making using the same.... Agent: Bozicevic, Field & Francis LLP

20080125369 - Soluble t cell receptors: The present invention provides a soluble T cell receptor (sTCR), which comprises (i) all or part of a TCRα chain, except the transmembrane domain thereof, and (ii) all or part of a TCR β chain, except the transmembrane domain thereof. (i) and (ii) each comprise a functional variable domain and... Agent: Banner & Witcoff, Ltd.

20080125361 - Stable formulations of peptides: Stable pharmaceutical composition comprising insulinotropic peptide.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20080125356 - Stable growth hormone liquid formulation: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of... Agent: Pharmacia Corporation Global Patent Department

20080125370 - Use of gelsolin to treat infections: The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.... Agent: Wolf Greenfield & Sacks, P.C.

20080125372 - Biologically active peptide vapeehptllteaplnpk derivatives: Peptides derived from the peptide CMS-010, which has the formula VAPEEHPTLLTEAPLNPK, are disclosed with their use as pharmaceutical compositions. A method is also disclosed for making a pharmaceutical composition comprising providing a peptide derived from CMS-010 and mixing said peptide with a pharmaceutical acceptable carrier.... Agent: EagleIPLimited

20080125373 - Mntf peptides and compositions and methods of use: The present invention is directed to novel peptides and compositions capable of modulating viability and growth in neuronal cells, and to methods of modulating neuronal cell viablility and growth employing the novel peptides and compositions of the invention. In one aspect, the invention is directed to novel peptide analogues of... Agent: Duane Morris LLP

20080125371 - Specific antagonists for glucose-dependent insulinotropic polypeptide (gip): In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II)... Agent: Edwards Angell Palmer & Dodge LLP

20080125374 - Gd3-mimetic peptides: GD3-Mimetic peptides which contain an amino acid sequence represented by any of SEQ ID NOS: 1 to 4 or an amino acid sequence derived therefrom by substitution, deletion, addition, or insertion of one or more amino acid residues and attaining specific binding to an anti-GD3 antibody; and medicinal compositions containing... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080125375 - Protease inhibitors: This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (I). Each variable is defined in the specification.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080125376 - Inhibitors of serine proteases, particularly hcv ns3-ns4a protease: or pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said... Agent: Michael C. Badia Vertex Pharmaceuticals Incorporated

20080125377 - Delivery system for antiangiogenic and antiinflammatory pharmaceuticals and method of use: Diseases and conditions associated with tissues of the body, including but not limited to tissues in the eye, can be effectively treated, prevented, inhibited, onset delayed, or regression caused by administering therapeutic agents to those tissues. Described herein are formulations which deliver a variety of therapeutic agents, including but not... Agent: Bausch & Lomb Incorporated

20080125378 - Use of amygdalin analogues for the treatment of psoriasis: The compounds of formula (1), wherein n is an integer from 0 to 4; R1 is a radical selected from the group consisting of H, CH3, CH2-CH3, C(CH3)3, COOH, CONH2 and C=CH; R2, R3, R4 and R5 are radicals independently selected from the group consisting of H, F, Cl, Br,... Agent: Berenbaum, Weinshienk & Eason, P.c

20080125379 - Drug and food or drink for improving pancreatic functions: 3-O-β-D-Glucopyranosyl-4-methyl-ergost-7-en-3-ol or a composition containing 0.001 to 10% by dry mass of the aforementioned compound, which is an extract of a plant of the family Liliaceae or a fraction thereof containing the compound, is used as an active ingredient of a drug for improving pancreatic functions.... Agent: Knobbe Martens Olson & Bear LLP

20080125380 - Fatty acid-anticancer conjugates and uses thereof: The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.... Agent: Wolf Greenfield & Sacks, P.C.

20080125381 - Imidazopyridine derivatives: The present invention relates to a novel imidazo[4,5-b]pyridine derivative compound represented by Formula (I) and a pharmaceutically acceptable salt thereof. The present invention also relates to a method for preparing the above compound. The present invention further relates to a pharmaceutical composition comprising the above compound. The above compound has... Agent: Birch Stewart Kolasch & Birch

20080125387 - Anemia: Disclosed is a viral vector containing a nucleic acid sequence encoding erythropoietin (Epo), in operable linkage with an HRE expression control sequence, as well as uses of the vector; for instance, in preparing a medicament. Also provided are methods for treating anemia, can involve administering the vector to a patient,... Agent: Frommer Lawrence & Haug

20080125382 - Extracellular superoxide dismutase (ec-sod) gene delivery to prevent oxidative injury: The present invention relates to compositions and methods for preventing oxidative injury to a cell. The compositions comprise a lipid formulation and a recombinant nucleic acid encoding an extracellular superoxide dismutase (EC-SOD), which upon transfection of a target cell is expressed by the cell and acts as an enzymatic antioxidant.... Agent: Townsend And Townsend And Crew, LLP

20080125389 - Men1 is a marker and therapeutic target for breast and prostate cancer: The present invention provides genomic markers for determining the presence or absence of breast cancer. The invention further demonstrates that inhibition of MEN1 reduces breast or prostate cancer proliferation, thereby demonstrating that inhibition of MEN1 activity or expression can be used to reduce breast cancer or prostate cancer proliferation in... Agent: Townsend And Townsend And Crew, LLP

20080125388 - Methods and compositions for cpg15-2: Disclosed herein are compositions of CPG 15-2 and methods for treating conditions of excessive cell death, such as neurological conditions, using such compositions. Compounds that inhibit the activity of CPG 15-2 are also disclosed herein for the treatment of conditions of undesirable cell survival, such as cancer.... Agent: Clark & Elbing LLP

20080125390 - Methods for modulating immune and inflammatory responses: A method for controlling leukaemia inhibitory factor (LIF)-interferon gamma inflammatory axis is provided. Control of interferon gamma production or release is mediated via modulation of the expression or activity of axotrophin (MARCH VII). Methods are provided for treating an animal that has received allografted tissue as well as for treating... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080125385 - Modulating phosphatase activity in cardiac cells: Expression of a phosphatase inhibitor in heart cells can be used to treat cardiac disorders, e.g., heart failure. Decreasing phosphatase activity can improve β-adrenergic responsiveness.... Agent: Ewards Angell Palmer & Dodge LLP (client: Mgh, Partners)

20080125383 - Modulators of coagulation factors with enhanced stability: The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary... Agent: King & Spalding LLP

20080125386 - Rna interference agents for therapeutic use: The invention features chemically modified small interfering RNAs (siRNAs) that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA. The features siRNA are effective therapeutics, particularly for targeting SOD1.... Agent: Lahive & Cockfield, LLP

20080125384 - Simultaneous silencing and restoration of gene function: Method and composition for simultaneously silencing an endogenously transcribed polynucleotide sequence in a cell using RNAi and replacing the function of the endogenous sequence with the function of an exogenous polynucleotide sequence. Also provided are methods of treatment based on the above method, and pharmaceutical composition comprising the vectors of... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC Attn: Kening Li

20080125391 - Tumor therapy with high affinity laminin receptor-targeted vectors: The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to... Agent: Darby & Darby P.C.

20080125392 - Glycolipids: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection is also described.... Agent: Townsend And Townsend And Crew, LLP

20080125393 - Methods of selectively treating diseases with specific glycosaminoglycan polymers: The present invention demonstrates that defined, specific GAG molecules have discerned differential effects, and that different types of cancers are prevented from proliferating and/or killed by oligosaccharides of different sizes; one size sugar does not treat all cancers effectively. Likewise, certain size GAGs have more potent angiogenic properties; thus, mixtures... Agent: Dunlap Codding & Rogers, P.C.

20080125394 - Oral compositions for absorption of phosphorus compounds: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from... Agent: Nixon & Vanderhye, PC

20080125395 - Compositions and methods for the treatment of skin: An ascorbic acid-based composition and related method for the treatment of aging, photo-damaged or inflamed skin is disclosed. The composition includes water and ascorbic acid, at least a portion of which has generally been pretreated by being dissolved under relatively high temperature and concentration conditions. The composition typically includes at... Agent: Wilson Sonsini Goodrich & Rosati

20080125396 - Derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators: The present invention relates to certain novel compounds of formula (I) to processes for preparing such compounds, to their the utility in modulation of nuclear hormone receptors Liver X Receptor (LXR) α (NR1H3) and/or β (NR1H2) and in treating and/or preventing clinical conditions including cardiovascular diseases such as atherosclerosis; inflammatory... Agent: Pepper Hamilton LLP

20080125397 - 2 (sulfonyl)ethyl n,n,n',n' tetrakis(2 chloroethyl)phosphorodia: 2-({2-Oxo-2-[(pyridin-3-ylmethyl)amino]ethyl}sulfonyl)ethyl N,N,N′,N′-tetrakis(2-chloroethyl)phosphorodiamidate and its acid addition salts, especially in solid form, their preparation and intermediates in their preparation, formulations containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.... Agent: Foley & Lardner LLP

20080125398 - 2-ethyl n,n,n',n'-tetrakis(2-chloroethyl)phosphorodiamidates: 2-{[2-(Substituted amino)ethyl]sulfonyl}ethyl N,N,N′,N′-tetrakis(2-chloroethyl)-phosphorodiamidates, their preparation and intermediates in their preparation, pharmaceutical compositions containing them, and methods of treatment using them. The compounds are useful for treating cancer, alone and in combination with other anticancer therapies.... Agent: Foley & Lardner LLP

20080125367 - Agents for treatment of hcv and methods of use: An amphipathic helix at the approximate N-terminus of Hepatitis C virus (HCV) nonstructural proteins mediates the association of these proteins with cytoplasmic membranes in infected cells. This association is essential for replication. Thus, assessing the ability of compounds or protocols to disrupt the association of such helices with cytoplasmic membranes... Agent: Bozicevic, Field & Francis LLP Stanford University Office Of Technology Licensing

20080125399 - 17 beta-acetamide-4-azasteroids as androgen receptor modulators: Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis,... Agent: Merck And Co., Inc

20080125400 - Use of phosphoenolpyruvate derivatives: or a physiologically acceptable salt thereof is administered to a patient to reduce or inhibit necrosis of cardiac muscle tissue as evidenced by a reduction in the levels of cardiac troponins in the blood. A particularly preferred derivative is phosphoenolpyruvic amide (“PEPA”), i.e. wherein X═O; Y═NH2; and Z1=Z2=OH.... Agent: Conley Rose, P.C. David A. Rose

20080125402 - Methods of hormonal treatment utilizing ascending-dose extended cycle regimens: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080125401 - Use of estradiol valerate or 17beta-estradiol in combination with dienogest for oral therapy to maintain and/or increase feminine libido: e

20080125405 - Composition for treating or preventing olfactory disorder: Disclosed is a composition for treating olfactory disorders, the composition comprising at least one statin-like drug, which is an HMG-CoA reductase inhibitor, as an active ingredient. The composition has excellent effects of protecting and regenerating olfactory nerve.... Agent: Edwards Angell Palmer & Dodge LLP

20080125403 - Method of treating men with metabolic and anthropometric disorders: A method of safely and specifically treating the combined metabolic disturbances of insulin resistance and visceral adiposity in male subject with visceral adiposity, metabolic syndrome (also known as the ‘insulin resistance syndrome’, and ‘syndrome X’), type II diabetes, or insulin resistance by administering a 5-alpha reductase inhibiting compound of structural... Agent: Merck And Co., Inc

20080125404 - Purine and pyrimidine cdk inhitbitors and their use for the treatment of autoimmune diseases: The present invention relates to the use of an inhibitor of CDK2 and/or CDK7 and/or CDK9, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating a disease associated with antinuclear antibodies, wherein the inhibitor of CDK2 and/or CDK7 and/or CDK9 or pharmaceutically acceptable salt thereof... Agent: Lahive & Cockfield, LLP

20080125406 - Method for treating primary and secondary forms of glaucoma: Methods and compositions for controlling ocular hypertension associated with (i) primary open angle glaucoma (POAG), (ii) other forms of glaucoma, or (iii) glucocorticoid therapy are disclosed. The methods involve administration of angiostatic agents and other IOP-lowering agents via local injections in the anterior segment of the eye. The most preferred... Agent: Alcon

20080125407 - Method for preparation of fluticasone propionate: Taught is a method for preparing S-fluoromethyl-6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate (fluticasone propionate). The present method is simple, convenient, and mild, yields highly pure product, and is suitable for use commercially on a large scale.... Agent: Matthias Scholl

20080125408 - Penem prodrug: u

20080125409 - 1,5-diheterocycle-1h-triazole derivative:

20080125410 - 1h-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use:

20080125411 - Dispiro 1,2,4-trioxolane antimalarials: A means and method for treating malaria, schistosomiasis, and cancer using a spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group. In comparison to artemisinin semisynthetic derivatives, the... Agent: Mckee, Voorhees & Sease, P.L.C

20080125412 - Polyarylcarboxamides useful as lipid lowering agents: m

20080125413 - Cgrp receptor antagonists: Compounds of Formula I: (where variables R1, R2, R3, R7, G, J, Q, T, W, X and Y are as defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache,... Agent: Merck And Co., Inc

20080125414 - Method of treatment: m

20080125415 - Novel methods for treatment of diseases related to activated lymphocytes: The present invention relates to inhibiting proliferation and inducing apoptosis in activated lymphocytes, including T cells and B cells. The invention also provides compositions and methods for inhibiting proliferation and inducing apoptosis in activated lymphocytes, as well methods for treating diseases associated with activated lymphocytes by administering 5-HT receptor antagonists.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080125418 - Benzimidazole derivatives and their use as kdr kinase protein inhibitors: wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080125417 - Certain pyrimidines, method of making, and method of use thereof: e

20080125416 - Sigma receptor inhibitors: The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved.... Agent: Morgan & Finnegan, L.L.P.

20080125419 - Benzothiazole derivatives with activity as adenosine receptor ligands: The present invention relates to substituted benzothiazole derivatives and to their pharmaceutically acceptable salts useful for the treatment of diseases related to the adenosine receptor.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080125420 - Synergistic insecticidal compositions: e

20080125421 - Synergistic insecticidal compositions:

20080125422 - Use of 5ht4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions: The invention also relates to the use of SB 207266 or a pharmaceutically acceptable salt thereof in the prophylaxis or treatment of atrial arrhythmia in a mammal by administration of the SB 207266 or salt thereof on the first day at a loading dose of about 1.2 to about 2.0... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080125423 - Fab i inhibitors: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.... Agent: Goodwin Procter LLP Patent Administrator

20080125424 - Derivatives of urea and related diamines, methods for their manufacture, and uses therefor: The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.... Agent: Amgen Inc.

20080125426 - Novel compounds: The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention also discloses processes for the preparation of... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20080125425 - Pyrrolo[3,2-d] pyrimidines that are selective antagonists of a2badenosine receptors: e

20080125429 - Aryloxy-substituted benzimidazole derivatives: [wherein R1 and R2 represent a hydrogen, etc.; R3 represents a hydrogen atom, a halogen atom, etc.; R4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with... Agent: Merck And Co., Inc

20080125428 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional EGFR and/or erbB-2 inhibitor. In particular, the method relates to methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080125427 - Novel inhibitors of rho-kinases: Novel inhibitors of Rho-kinases are disclosed.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20080125430 - New small molecule inhibitors of mdm2 and the uses thereof: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).... Agent: Casimir Jones, S.c.

20080125431 - Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the... Agent: Birch, Stewart, Kolasch & Birch, LLP

20080125432 - 5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the kv family: wherein X, Y1, Y2, R1, n, R3, R8, R9, R10, L1, L2, Ar1 and Ar2 are defined in claim 1. The invention also relates to methods for preparing said compounds, to pharmaceutical compositions comprising said compounds, and to the use of said compounds in methods for treatment of the human... Agent: Wolf Greenfield & Sacks, P.C.

20080125433 - Method of treating hair loss using thyromimetic compounds: The present invention provides methods and compositions for treating hair loss, including arresting and/or reversing hair loss and/or promoting hair growth, in mammals, such as humans, companion animals and livestock, using certain thyromimetic compounds.... Agent: Pfizer Inc.

20080125434 - Heterocyclic derivatives and their use as strearoyl-coa desaturase inhibitors: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8... Agent: Seed Intellectual Property Law Group PLLC

20080125435 - 1-(het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the ep2 receptor: The present invention relates to aryl-3-[(het)aryl-piperidin-4-yl]-thioureas, processes for the production thereof and the use thereof for the production of pharmaceutical agents for the treatment of diseases and indications which are connected with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20080125436 - Mglur5 modulators: e

20080125438 - Allosteric modulators of the a1 adenosine receptor: wherein R1, R2, R3, R4 and Q have a meaning as defined herein in the specification. The compounds of formula (I) are allosteric modulators of the A1 adenosine receptor and, thus, may be employed for the treatment of conditions mediated by the A1 adenosine receptor. Accordingly, the compounds of formula... Agent: Christopher A. Klein King Pharmaceuticals, Inc.

20080125437 - Mapk/erk kinase inhibitors: e

20080125439 - Diazaindole-dicarbonyl-piperazinyl antiviral agents:

20080125440 - Tyrosine kinase inhibitors containing a zinc binding moiety: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080125441 - Spiro and dispiro 1,2,4-trioxolane antimalarials: A means and method for treating malaria, schistosomiasis, and cancer using a Spiro or dispiro 1,2,4-trioxolane is described. The preferred 1,2,4-trioxolanes include a spiroadamantane group on one side of the trioxolane group, and a spirocyclohexyl on the other side of the trioxolane group, whereby the spirocyclohexyl ring is preferably substituted... Agent: Mckee, Voorhees & Sease, P.L.C

20080125442 - Cathepsin k inhibitors and atherosclerosis: This invention relates to a genus of compounds, represented by the formula (I) diagrammed below, wherein the meanings of R1, R2, R3, R4, R5, R6, R7, R8, D and n are indicated therein, which are inhibitors of cathepsin K. These compounds are useful for treating or preventing atherosclerosis and atherosclerotic... Agent: Merck And Co., Inc

20080125443 - Cardioprotective delta opioid receptor agonists and methods of using same: The present invention relates to compositions and methods of treatment for cardioprotection through the use of non-peptidic delta opioid receptor agonist compound(s) that mediate cardioprotective effects of ischemic preconditioning. The compounds are used to reduce injury associated with ischemia and reperfusion of cardiac tissue. Further, the compounds may be used... Agent: Moore & Van Allen PLLC

20080125444 - Acyclic oximyl hepatitis c protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20080125445 - 5,6-dialkyl-7-amino-azolopyrimidines, method for their production, their use for controlling pathogenic fungi and agents containing said compounds: i

20080125446 - Purine analogs having hsp90-inhibiting activity: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.... Agent: Biogen Idec / Finnegan Henderson, LLP

20080125447 - Combination therapy: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour,... Agent: Morgan Lewis & Bockius LLP

20080125448 - Quinazoline based egfr inhibitors containing a zinc binding moiety: The present invention relates to quinazoline containing zinc-binding moiety based derivatives that have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer.... Agent: Elmore Patent Law Group, PC

20080125449 - Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers: The present invention is directed in part towards methods of modulating the function of calcium channels with pyrimidine-based compounds. In addition, the invention describes methods of preventing and treating calcium channel-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pyrimidine-based compounds and... Agent: Knobbe Martens Olson & Bear LLP

20080125450 - Pharmaceutical compositions comprising a camptothecin derivate: The present invention relates to novel pharmaceutical compositions in which the active agent is a topoisomerase I inhibitor, in particular a camptothecin derivative, that is useful for the treatment and prevention of proliferative diseases including cancer.... Agent: Novartis Corporate Intellectual Property

20080125451 - Vinorelbine derivatives: The present invention relates to novel vinorelbine derivatives. Pharmaceutical compositions containing these compounds as well as processes of preparation and processes of use for treatment of various conditions are also disclosed.... Agent: Nixon Peabody LLP - Patent Group

20080125452 - Indolopyridines,benzofuranopyridines and benzothienopyridines: e

20080125453 - Phenylephrine tannate, pyrilamine tannate and dextromethorphan tannate salts in pharmaceutical compositions: Compositions of tannate salts of phenylephrine, pyrilamine, and dextromethorphan produced by a method that allows for the in-situ conversions and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving salts of phenylephrine, pyrilamine, and dextromethorphan in a solvent and mixing with a dispersing agent... Agent: Moore & Van Allen PLLC

20080125455 - Condensed indoline derivatives and their use as 5ht, in particular 5ht2c, receptor ligands: A chemical compound of formula (I) wherein R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 and R5 are selected from hydrogen and alkyl; R6 and R7 are independently selected from hydrogen, halogen, hydroxyl, alkyl, aryl, amino, alkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, alkylsulfoxyl, nitro, carbonitrile,... Agent: Foley And Lardner LLP Suite 500

20080125454 - Methods and compositions for treatment of scleritis and related disorders: c

20080125456 - Injection of tacrolimus: This invention relates to tacrolimus injection comprising tacrolimus as an active ingredient, macrogol 15 hydroxystearate as a surfactant and a non-aqueous solvent.... Agent: Sughrue Mion, PLLC

20080125457 - O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080125459 - N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and therapeutic use thereof: e

20080125458 - Novel crystalline form of cyano-1-cyclopropyl-7-1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl) -6-fluoro-1,4-dihydro-4-oxo-3-quinoline carboxylic acid: The present invention relates to the trihydrate of pradofloxacin, to a process for its preparation and to antibacterial compositions comprising them.... Agent: Bayer Healthcare LLC

20080125460 - Imidazopyridine-derivatives as inducible no-synthase inhibitors: e

20080125461 - (r,r)-formoterol in combination with other pharmacological agents: This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (R,R)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (R,R)-formoterol and other pharmacological agents are also disclosed.... Agent: Jones Day

20080125462 - Cinnamate salts of a beta-2 adrenergic agonist: This invention relates to cinnamate salts of 5-[(R)-2-(2-{4-[4-(2-amino-2-methyl-propoxy)-phenylamino]-phenyl}-ethylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080125463 - N-(1-hetarylpiperidin-4-yl)(het)arylamides as ep2 receptor modulators: The present invention relates to (het)aryl-3-[(het)arylpiperidin-4-yl]amides, to processes for their preparation and to their use for producing pharmaceutical compositions for treatment of disorders and indications connected to the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20080125464 - Prucalopride n-oxide: The present invention is concerned with a novel benzamide derivative and the pharmaceutically acceptable acid addition salts thereof, pharmaceutical compositions comprising said novel compound, processes for preparing said compounds and compositions, and the use thereof as a medicine in the treatment of gastrointestinal motility disorders.... Agent: Philip S. Johnson Johnson & Johnson

20080125465 - Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex: This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene... Agent: Intrexon Corporation

20080125466 - Aryl-substituted benzo[d]isothiazol-3-ylamine analogues: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods... Agent: Edwards Angell Palmer & Dodge LLP

20080125467 - Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof: The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.... Agent: Morrison & Foerster LLP

20080125468 - Glucagon receptor antagonists, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20080125469 - Thiadiazole compounds and methods of use thereof: The present invention relates to Thiadiazole Compounds; compositions comprising an effective dose of a Thiadiazole Compound; and methods treating or preventing a metalloproteinase-related disorder, such as, an arthritic disorder, osteoarthritis, cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, atherosclerosis, age-related macular degeneration, myocardial infarction, a corneal ulceration, an ocular surface... Agent: Wilmerhale/wyeth

20080125470 - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.... Agent: Fish & Richardson PC

20080125471 - Water-soluble tetrazolium salts: Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkylammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings attached to the tetrazolium ring. Thiazolyl tetrazolium salts with increased solubility in aqueous solutions have alkyl ammonium alkoxy substituents, preferably trimethyl ammonium propoxy groups substituents, on phenyl rings... Agent: Nixon Peabody LLP

20080125472 - Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure: The present invention relates to use of an inhibitor of the renin-angiotensin system (RAS) or a pharmaceutically acceptable derivative thereof, such as ramipril or ramiprilat, in the prevention of stroke, diabetes and/or congestive heart failure (CHF).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080125473 - Substituted imidazoles: This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.... Agent: Pharmacia & Upjohn

20080125474 - Pyrazole analogs: or a pharmaceutically acceptable salt and solvate thereof, wherein R1 is F or H and to processes for the preparation of, intermediates used in the preparation of, compositions containing the uses of, such compounds. The compounds according to the present invention are useful in numerous diseases, disorders and conditions, in... Agent: Pfizer Inc.

20080125475 - Mixed orl1/mu-agonists for the treatment of pain: The invention relates to the use of compounds which exhibit an affinity for the μ-opioid receptor of at least 100 nM (Ki value, human) and an affinity for the ORL-1 receptor, wherein the ratio between the affinities ORL1/μ defined as 1/[Ki(ORL1)/Ki(μ)] is from 0.1 to 30, for the treatment of... Agent: Norris, Mclaughlin & Marcus, Pa

20080125476 - Carvedilol phosphate: The invention encompasses novel amorphous and crystalline forms of carvedilol phosphate, carvedilol hydrogen phosphate, and carvedilol dihydrogen phosphate as well as methods of making the novel amorphous and crystalline forms. Also disclosed are pharmaceutical compositions comprising the novel amorphous and crystalline forms and uses thereof.... Agent: Kenyon & Kenyon LLP

20080125477 - 7-(acryloyl) indole compositions and methods of making and using same: e

20080125478 - Substituted 2-indolinone as ptk inhibitors containing a zinc binding moiety: The present invention relates to substituted 2-indolinone containing zinc-binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.... Agent: Elmore Patent Law Group, PC

20080125479 - Wortmannin analogs and methods of using same: Novel Wortmannin analogs and their use in inhibiting inhibiting PI-3-kinase activity in mammals as well, as tumor formation in a subject are described herein.... Agent: Pepper Hamilton LLP

20080125480 - Oil-in-water formulation of avermectins: Oil-in-water emulsion formulations (EW) of avermectins based on phthalates as organic solvent and the use of such formulations for the control of pests.... Agent: Jacobson Holman PLLC

20080125481 - Isoflavone metabolites: l

20080125482 - Stabilized ascorbic acid solutions; method of use thereof; process for their obtention; and compositions comprising the same: This invention relates to improved solutions comprising ascorbic acid (vitamin C). These solutions may comprise as much as 15% ascorbic acid; they are stable for at least two years, without no significant development of yellowish coloration and no substantial (not more than 10%) degradation of the vitamin. The process involves... Agent: Goudreau Gage Dubuc

20080125483 - Gaba analogs, compositions and methods for manufacturing thereof: The invention provides novel compounds of Formula (I), pharmaceutical compositions and methods of synthesis thereof.... Agent: Winston & Strawn LLP Patent Department

20080125484 - Synthetic lactone formulations and methods of use: Natural and synthetic compounds having a lactone structure methods for using and making the compounds have been disclosed. The compounds are useful as anti-bacterial, anti-fungal and anti-inflammatory agents, and for treating proliferation disorders such as melanoma, leukemia, breast cancer, lung cancer, ovarian cancer, colon cancer, esophagus cancer, liver cancer, and... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080125486 - Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ: The present invention refers to the use of the compound of Formula (I′) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates... Agent: Frommer Lawrence & Haug

20080125485 - Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or phrophylactic treatment of, inter alia, actinic keratosis.... Agent: Frommer Lawrence & Haug

20080125487 - Elongase gene and uses thereof: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “Δ9-elongase”) and to uses thereof. In particular, Δ9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid... Agent: Ross Products Division Of Abbott Laboratories Department 108140-ds/1

20080125488 - Lactate containing pharmaceutical composition and uses thereof: The invention relates to a pharmaceutical composition containing 250 to 2400 millimoles per liter of lactate or lactic acid, 2 to 10 millimoles per liter of potassium cation and optionally 2 to 5 millimoles per liter of calcium cation. The invention also relates to pharmaceutical uses of this composition. The... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20080125489 - Methods and compositions for the treatment and prevention of lung disease: Methods and compositions for the treatment of lung disease such as emphysema and/or bronchopulmonary dysplasia in a mammal. Also disclosed are methods and compositions promoting the formation of alveolar septa and increasing the gas-exchange surface area of a mammalian lung, and for the prevention and/or treatment of alveolar destruction.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080125490 - Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering omega-3 fatty acids: Compositions comprising omega-3 fatty acids are provided, where the compositions are useful for treating cardiovascular disease in patients suffering from chronic kidney disease (CKD), preventing its further progression, and treating underlying risk factors such as hypertension, dyslipidemia, obesity and/or diabetes. Also provided are methods of using the compositions to reduce... Agent: Arent Fox LLP

20080125491 - Human g protein-coupled receptor and modulators thereof for the treatment of cell death-related disorders: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In certain embodiments, the GPCR is human. In certain embodiments, the GPCR is expressed endogenously by neuronal cells or muscle cells. In certain embodiments, the GPCR is neuroprotective or... Agent: Bozicevic, Field & Francis LLP (arena Pharmaceuticals, Inc.)

20080125492 - Medicaments containing panthenol: This invention relates to medicaments and their use in the alleviation of inflammation and pain in joints.... Agent: Fish & Richardson PC

20080125493 - Use of agomelatine in obtaining medicaments intended for the treatment of periventricular leukomalacia: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of periventricular leukomalacia.... Agent: The Firm Of Hueschen And Sage

20080125494 - Alkylamine as an antimicrobial agent in ophthalmic compositions: where R1 is a C13-17 alkylamine, and R2 and R3 are each independently H or —CH3, and a non-ionic surfactant. The solution may optionally also include additional antimicrobial components, a buffer component, a viscosity inducing component, a surfactant, taurine, propylene glycol and/or a tonicity component. This solution additionally prevents losses... Agent: Advanced Medical Optics, Inc.

20080125495 - Ameliorant for renal insufficiency: e

20080125496 - Antimicrobial flavor and oral care composition containing the same: The present invention provides antimicrobial flavors and flavor compositions which are of high safety and little influential on intestinal bacteria, as well as oral care compositions and foods containing the same. The flavor is selected from dihydrofarnesol, isocamphylcyclohexanol, levosandol, bacdanol, Santalinol, methyl atrarate, 10-undecen-1-ol, 2-methyl undecanal, sandalol, dodecanal, brahmanol, neroridol,... Agent: Sughrue Mion, PLLC

20080125497 - Tagetes erecta marigolds with altered carotenoid compositions and ratios: A marigold plant, a regenerable portion thereof and seed are disclosed whose flower petals, leaves or flower petals and leaves contain one or more of an enhanced neoxanthin plus violaxanthin ratio, an enhanced β-carotene ratio, an enhanced lycopene ratio, an enhanced α-cryptoxanthin ratio, an enhanced phytoene ratio or an enhanced... Agent: Welsh & Katz, Ltd

20080125498 - Treatment of neurodegenerative diseases and conditions using par1 antagonists: The present invention features methods for treating and/or preventing neurodegenerative and/or neurotoxic diseases, conditions, and injuries, by inhibiting the activity of protease-activated receptor-1 (PAR1) on neurons and glial cells using PAR1 antagonists.... Agent: Needle & Rosenberg, P.C.

20080119387 - Compositions and methods for regulating peptidyltransferase activity and uses thereof: The present invention provides compositions and means to identify compositions that increase −1 PRF programmed ribosomal frameshift (−1PRF) efficiencies and/or decrease peptidyltransferase activity in a cell, and thus directly affect viral replication or assembly of viral particles. Compositions identified in accordance with the invention specifically inhibit the interaction between ribosomal... Agent: Elmore Patent Law Group, Pc

20080119389 - Compositions comprising epigallocatechin gallate and protein hydrolysate: The present invention describes a composition comprising EGCG and a protein hydrolysate.... Agent: Nixon & Vanderhye, Pc

20080119388 - Methods of using sip-10 to assess hcv clearance and/or response to interferon therapy: The present invention relates to methods for evaluating and predicting clinical outcomes in patients by measuring levels of sIP-10 protein expression as well as therapies using sIP-10 and its fragments.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20080119385 - Modified two-component gelation systems, methods of use and methods of manufacture: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components... Agent: Blakely Sokoloff Taylor & Zafman

20080119386 - Nutritional formula for athletes' recovery: A nutritional composition for athletes comprising in combination components for reducing oxidative stress, components for energy production and for maintaining lean muscle, the key component of which is SOD/gliadin.... Agent: Schweitzer Cornman Gross & Bondell LLP

20080119390 - Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus: Synthetic peptides of at least 12 and at most 30 amino acid residues comprising a sequence consisting of, or found within, a complementarity-determining region (CDR) found in the heavy or light chain of the human anti-DNA 16/6Id monoclonal antibody, or a sequence obtained by replacement and/or deletion and/or addition of... Agent: John P. White Cooper & Dunham LLP

20080119384 - Use of tpo peptide compounds and pharmaceutical compostions in the treatment of anemia: Peptide compounds that bind to and activate the thrombopoietin receptor (c-mpl or TPO-R) or otherwise act as a TPO agonist are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080119392 - Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption: Methods and devices for administration of substances into the intradermal layer of skin for systemic absorption.... Agent: Jones Day

20080119393 - Novel exendin agonist compounds: Novel exendin agonist compounds are provided. These compounds are useful in treating diabetes and conditions which would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20080119394 - Unitary combinations of fsh and hcg: A novel ovulatory induction paradigm entails administration of hCG in combination with FSH during all stages of treatment, where the ratio of FSH to hCG is adjusted to optimize ovulatory stimulation and minimize complications. The use of compositions characterized by various FSH:hCG ratios enables the practitioner readily to tailor the... Agent: Foley And Lardner LLP Suite 500

20080119396 - Tgf derepressors and uses related thereto: The application is directed to TGF analogs/derepressors that bind to and neutralize cystine knot-containing BMP antagonists—such as the CAN subfamily of Cystine-knot proteins including sclerostin. The subject TGF derepressors can be prepared as substantially pyrogen-free pharmaceutical compositions for administration to mammals, in treating diseases such as bone diseases including osteoporosis,... Agent: Ropes & Gray LLP

20080119401 - Analogs of parathyroid hormone: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate... Agent: Biomeasure, Incorporated

20080119404 - Antiobesity drug: An antiobesity agent, an antidiabetic agent, and/or a hypolipidemic agent comprising an angiopoietin-related growth factor (AGF) or a polynucleotide encoding the same as an active ingredient a polypeptide are disclosed. Further, a functional food or a health food for alleviating obesity, diabetes, and/or hyperlipemia, comprising the AGF as an active... Agent: Sughrue Mion, Pllc

20080119402 - Compositions and methods for the inhibition of dishevelled proteins: The Wnt signaling pathways are involved in embryo development as well as in tumorigenesis. Dishevelled (Dvl) tranduces Wnt signals from the receptor Frizzled (Fz) to downstream components in canonical and non-canonical Wnt signaling pathways, and the Dvl PDZ domain plays an essential role in both pathways, and the Dvl PDZ... Agent: Enzo Biochem, Inc.

20080119399 - Epidermal growth factor receptor-derived peptides: e

20080119405 - Fowlicidins and methods of their use: Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”).... Agent: Fellers Snider Blankenship Bailey & Tippens

20080119403 - Haparin-binding protein modified with heparan sulfate sugar chains, process for producing the same and pharmaceutical compositions containing the same: A heparin-binding protein having covalently bonded heparan sulfate sugar chains within its molecule is produced by ligating a cDNA encoding a peptide which can be modified with heparan sulfate sugar chains selectively to a cDNA encoding a heparin-binding protein and producing in an animal cell the gene product of the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080119409 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol): The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080119398 - Modified thioredoxin: ABSTRACT The present invention relates to a human modified thioredoxin composed of any of the following polypeptides:(a) a polypeptide modified by alteration or chemical modification of a cysteine residue at position 35 with another amino acid in an amino acid sequence of SEQ ID NO:2; and (b) a polypeptide having... Agent: Knobbe Martens Olson & Bear LLP

20080119400 - Modified truncated complement system regulators: Analogs of regulators of complement activation (RCA) proteins which have altered specificities and affinities for the targets C3b and/or C4b are described. These analogs are obtained by substituting amino acids which affect the complement inhibitory activities of these proteins, substituting, rearranging or adding SCRs (short consensus repeats) or SCR regions... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20080119410 - Modulation of pericyte proliferation: Methods and materials for modulating pericyte and epithelial cell proliferation relating to BPI protein products or inhibitors thereof are provided.... Agent: Anne Dollard Xoma (us) Llc

20080119406 - Osteoblast growth factor: The present invention provides to the isolation of a small cysteine rich secretory protein from a haematopoietic macrophage cell line, which is capable of elevating cytosolic calcium levels. In particular, the present invention provides a method of treating or preventing bone disorders or diseases comprising the step of administering a... Agent: Duane Morris, LLP Ip Department

20080119408 - Pth formulations for intranasal delivery: What is described is an aqueous pharmaceutical formulation for intranasal delivery of PTH, consisting essentially of PTH(1-34) and sorbitol; or PTH(1-34), sorbitol, and a surface active agent; or PTH(1-34), sorbitol, and halogenated alkyl alcohol; or PTH(1-34), sorbitol, a surface active agent, and a halogenated alkyl alcohol.... Agent: Nastech Pharmaceutical Company Inc

20080119407 - Vitamin d receptor modulators: The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R′, RP, RP3, LP1, LP2, ZP, RB, RB′, LXB and ZXB are as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.... Agent: Eli Lilly & Company

20080119412 - Polypeptides for modulating binding of trp channel proteins and trp- associated proteins: This invention relates to inhibitors and modulators of the binding between a transcient receptor potential (TRP) channel protein and a TRP-associated binding protein. In particular inhibitors and modulators of the binding between the TRPM7 channel protein and PDZ-domain containing TRP-associated proteins. These modulators and inhibitors are used to control Ca2+... Agent: Townsend And Townsend And Crew, LLP

20080119413 - Low density cosmetic formulations, cosmetic products containing the same and methods of treating hair, nails and/or skin using the same: Low density cosmetic formulations which comprise: (a) a cosmetic mixture; and (b) a gas incorporated in the cosmetic mixture; wherein the cosmetic mixture comprises (i) an alk(en)ylpolyglycoside, (ii) a quaternary ammonium polymer, and (iii) a thickener, are described along with suitable cosmetic mixtures for forming such low density formulations, methods... Agent: Connolly Bove Lodge & Hutz LLP

20080119414 - Mixtures of quaternary and non-ionic surfactants: wherein, R2 is a linear or branched alkyl and/or alkenyl group containing 4 to 22 carbon atoms, G is a sugar unit containing 5 or 6 carbon atoms, x is a number of 1 to 10, y is a number of 1 to 4 and Z is an —OCH2—(CH(B))v—(CH(A))w-N+(R3R4R5)X− group,... Agent: Cognis Corporation Patent Department

20080119415 - Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds: Methods and compositions for treating or ameliorating diseases and other conditions, such as infectious diseases, autoimmune diseases and allergies are provided. The methods employ mono- and disaccharide-based compounds for selectively stimulating immune responses in animals and plants.... Agent: Townsend And Townsend And Crew, LLP

20080119416 - New steroids having increased water solubility and resistance against metabolism, and methods for their production: Steroid compounds having increased resistance against metabolism and increased water solubility are disclosed, together with methods for their production. These substances are suitable for the manufacture of pharmaceuticals for the treatment of steroid related or steroid induced CNS disorders and for use in methods of prevention, alleviation or treatment of... Agent: Morrison & Foerster LLP

20080119417 - Metabolic syndrome-improving agent and medicine, supplement, functional food and food additive containing the same: A metabolic syndrome relieving agent that is free from a problem of side effects and can be taken for a long term is provided. Aurapten is used as an agent for relieving a metabolic syndrome. Since aurapten has functions of activating PPARα and PPARγ, promoting the secretion of adiponectin in... Agent: Hamre, Schumann, Mueller & Larson, P.c.

20080119418 - C-9 alkenylidine bridged macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, Pc

20080119420 - Saponins derived from ilex pubescens and method of purifying the same: Two hitherto unreported novel triterpene saponins were isolated in substantially pure form from the root of Ilex pubescens. The chemical structures and some properties of the triterpene saponin fraction have been elucidated to possess anti-inflammatory and analgesic activity. These two novel triterpene saponins and the triterpene saponin fraction may be... Agent: Eagle Ip Limited

20080119421 - Process for treating a biological organism: A process for treating a biological organism, comprising the steps in which a cell cycle arresting drug is administered to the organism to produce synchronized cells, the microtubules within the synchronized cells are stabilized by means of a microtubule stabilizing agent, and the synchronized cells with the stabilized microtubules are... Agent: Buchanan Ingersoll Pc Including Attorneys From Burns, Doane,

20080119422 - Indole derivatives: p

20080119425 - Clusterin antisense therapy for treatment of cancer: A method for providing antisense therapy which reduces the expression of clusterin to provide therapeutic benefits in the treatment of cancer comprising administering from 40 to 640 mg anti-clusterin antisense oligonucleotide to a patient in need of treatment for a cancer expressing clusterin is provided. The method may include administering... Agent: Marina Larson & Associates, Llc

20080119424 - Combined use of prame inhibitors and hdac inhibitors: The invention relates to the cancer antigen PRAME (PReferentially expressed Antigen in MElanoma) and its use in a method of treatment of a tumour which comprises administering to a subject in need of treatment an effective amount of an inhibitor of PRAME, in combination with a second agent selected from... Agent: Nixon & Vanderhye, Pc

20080119430 - Compositions and methods for angiogenesis-related molecules and treatments: Short interfering RNA (siRNA) molecules which modulate the expression of an angiogenesis-related gene by RNA interference are described. Short hairpin RNA (shRNA) molecules comprising said siRNA molecules are also described. These molecules can target all, or specific, isoforms of the gene. The use of these molecules and of isoforms of... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080119433 - Compositions and methods for genetic modification of cells having cosmetic function to enhance cosmetic appearance: Disclosed are methods and compositions to genetically modify substantially intact cells having cosmetic function to enhance the cosmetic appearance in mammals so as to enhance and/or maintain a biochemical and/or physiological process that has a positive effect on cosmetic appearance. The methods and compositions may provide cosmetic benefits such as... Agent: Kilpatrick Stockton LLP

20080119426 - Compositions and methods for the treatment of muscle wasting: The invention provides compositions of oligonucleotides targeted at genes involved in muscle wasting and/or muscle growth. In some embodiments, the oligonucleotides are modified. In some embodiments, the compositions contain one, or more than one, oligonucleotide. The invention also provides methods and kits using the compositions of the invention for the... Agent: Patent Docket Administrator Lowenstein Sandler Pc

20080119427 - Double strand compositions comprising differentially modified strands for use in gene modulation: The present invention provides douse stranded compositions wherein each strand is modified to have a motif defined by positioning of β-D-ribonucleosides and sugar modified nucleosides. More particularly, the present compositions comprise one strand having a gapped motif and another strand having a gapped motif, a hemimer motif, a blockmer motif,... Agent: Woodcock Washburn LLP

20080119435 - Hes6 as a marker of pancreatic endocrine cells: The present invention provides methods of identifying endocrine stem and progenitor cells.... Agent: Townsend And Townsend And Crew, LLP

20080119432 - Inhibition of metallo-beta-lactamase by rna: Compositions and methods for identifying polyribonucleotides that binds with high affinity to a metallo-β-lactamase. The polyribonucleotides inhibit the activity of the metallo-β-lactamase.... Agent: Jackson Walker LLP

20080119428 - Method for diagnosing non-small cell lung cancers by trna-dihydrouridine synthase activity of urlc8: The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for... Agent: Townsend And Townsend And Crew, LLP

20080119423 - Methods and materials for modulating p2x2: The invention relates to antisense oligonucleotides, compositions and methods useful for modulating the expression of P2X2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding P2X2.... Agent: Fish & Richardson P.c.

20080119429 - Methods and means for increasing resistance to cell damage: Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasing the amount of functional eEF2... Agent: Synnestvedt Lechner & Woodbridge LLP

20080119431 - Per-6-guanidino-, alkylamino-cyclodextrins, methods of their synthesis and their use for the compaction of dna and interacellular delivery: The invention relates to new compounds of type hexakis(6-deoxy-6-NH(CH2)n, —R1)α-cyclodextrin and heptakis(6-deoxy-6-NH(CH2)n—R1)-(β-cyclodextrin, and octakis(6-deoxy-6-NH(CH2)n—R1)-γ-cyclodextrin, where n=2-6 when R1═NH2 and n=0 when R1═C(═NH)NH2 and n=2-6 when R1═NH—